STOCK TITAN

Evofem Biosciences completes 1-for-1,500 reverse split

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Evofem Biosciences, Inc. (EVFM) made a 1-for-1,500 reverse stock split effective at the open of trading on November 18, 2026. Common shares outstanding changed from approximately 132,530,081 as of November 17, 2026, to approximately 88,353. The company’s total authorized common stock remains unchanged.

The split proportionally adjusts exercise and conversion prices and share counts for outstanding options, warrants, convertible notes and stock incentive plans. The common stock trades under EVFMD for 20 business days, then is to continue under EVFM. Shareholders holding shares electronically or through a broker are not required to take action; the transfer agent will send instructions to holders of physical certificates.

Filing Explained

The effective 1-for-1,500 split reduces outstanding shares while leaving authorized common shares unchanged; the company says its aim is to ensure authorized-share capacity covers shares underlying its financial instruments.

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Governance
The company amended its charter documents, bylaws, or changed its fiscal year.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Reverse stock split ratio 1-for-1,500 Effective November 18, 2026
Common shares outstanding before split Approximately 132,530,081 shares As of November 17, 2026
Common shares outstanding after split Approximately 88,353 shares Expected following the reverse stock split
EVFMD symbol period 20 business days The common stock is then to continue under EVFM
reverse stock split technical
"effect a one-time reverse stock split of the Company’s Common Stock"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
fully diluted basis financial
"underlying the Company’s financial instruments on a fully diluted basis"
A fully diluted basis counts every share that could exist if all outstanding options, warrants, convertible securities and other rights were exercised or converted into common stock, showing the maximum number of shares outstanding. For investors this matters because it spreads ownership and earnings across that larger share count, like slicing a pie into every possible piece before deciding how big each investor’s slice will be, which affects per-share value and ownership percentage.
convertible notes financial
"exercise and conversion prices of the Company’s outstanding stock options, warrants, purchase rights, and convertible notes"
Convertible notes are a type of short-term loan that a company receives from investors, which can later be turned into company shares instead of being paid back in cash. They matter to investors because they offer a way to support a company early on while giving the potential to own a stake in its success if the company grows and later raises more funding.
book-entry form technical
"holding their shares electronically in book-entry form"
A book-entry form is an electronic record showing ownership of securities instead of a paper certificate; think of it like a bank account ledger that notes who owns shares. It matters to investors because it makes buying, selling and transferring securities faster, safer and cheaper by reducing paperwork, loss or forgery risk, and enabling easier settlement through brokers or a central depository.
Split Ratio 1-for-1,500 reverse split
Effective Date November 18, 2026
Shares Before Split 132,530,081
Shares After Split 88,353
Share Count As Of November 17, 2026

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many EVFM shares remain outstanding after the reverse split?

Approximately 88,353 shares were expected to remain outstanding after the 1-for-1,500 reverse split, compared with approximately 132,530,081 shares outstanding as of November 17, 2026.

When will Evofem’s stock symbol change back from EVFMD to EVFM?

After 20 business days, the common stock is to continue trading on the OTCID under the symbol EVFM; during that period, the symbol is EVFMD.

Do EVFM shareholders need to take action for the reverse split?

Electronic and broker-held shares are adjusted without action by shareholders. Holders of physical stock certificates will receive instructions from the company’s transfer agent for exchanging their certificates.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false --12-31 0001618835 0001618835 2026-11-18 2026-11-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): November 18, 2026

 

EVOFEM BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-36754   20-8527075
(State or other jurisdiction   (Commission   (I.R.S. Employer
of incorporation)   File Number)   Identification No.)

 

7770 Regents Road, Suite 113-618

San Diego, California 92122

(Address of principal executive offices)

 

(858) 550-1900

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of exchange on which registered
None        

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging Growth Company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

 

At the Annual Meeting of Evofem Biosciences, Inc. (the “Company”) held on November 26, 2025 (the “Annual Meeting”), the Company’s shareholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”), as amended, to effect a one-time reverse stock split of the Company’s Common Stock, to effectuate a reverse stock split of the outstanding shares of the Company’s common stock by a ratio of not less than 1-for-500 and not more than 1-for-1,500 at any time on or prior to November 26, 2026, with the exact ratio to be set at a whole number within such range by the Company’s board of directors (the “Board”), at the sole discretion of the Company (the “Reverse Stock Split”). The Company determined it was in the best interest of the Company to effect a reverse split at a ratio of 1-for-1,500. The Company’s total authorized Common Stock remains unchanged.

 

On November 5, 2026, the Company filed with the Secretary of State of the State of Delaware the Certificate of Amendment to effectuate the Reverse Stock Split at a ratio of 1-for-1,500, in accordance with the General Corporation Law of the State of Delaware, effective upon effectiveness of the Certificate of Amendment. On November 17, 2026, the Company filed with the Secretary of State of the State of Delaware a Certificate of Correction (the “Certificate of Correction”) to change the effective time of the Reverse Stock Split from November 5, 2026 to November 18, 2026. As a result, the Reverse Stock Split become effective upon the open of trading on the OTCID on November 18, 2026 (the “Effective Time”). The Company’s Common Stock will trade on the OTCID under the symbol “EVFMD”, and after twenty (20) business days, the Company’s Common Stock will continue to trade on the OTCID under the symbol “EVFM. “ The new CUSIP number for the common stock following the Reverse Stock Split is 30048L401.

 

At the Effective Time, every 1,500 shares of the Company’s issued and outstanding Common Stock (and such shares held in treasury) was automatically converted into one share of Common Stock, without any change in the par value per share. In addition, proportionate adjustments will be made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding stock options, stock appreciation rights, convertible notes and warrants to purchase shares of Common Stock, the number of shares issuable upon the vesting of all restricted stock awards, and the number of shares of Common Stock reserved for issuance pursuant to the Company’s equity incentive compensation plans. Any stockholder who was otherwise be entitled to a fractional share of Common Stock created as a result of the Reverse Stock Split shall be entitled to receive a cash payment equal to the product of such resulting fractional interest in one share of Common Stock multiplied by the closing trading price of the Common Stock on the trading day immediately preceding the Effective Time, which was $0.0043.

 

The above descriptions of the Certificate of Amendment, the Certificate of Correction, and the Reverse Stock Split is qualified in its entirety by reference to the Certificate of Amendment and Certificate of Correction, copies of which are attached hereto as Exhibits 3.1 and 3.2, respectively, and incorporated herein by reference.

 

Item 7.01. Regulation FD Disclosure

 

On November 18, 2026, the Company issued a press release announcing the above referenced Reverse Stock Split. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8 -K.

 

The information set forth under Item 7.01 of this Current Report on Form 8 -K (this “Current Report”), including Exhibit 99. 1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section. The information in Item 7. 01 of this Current Report, including Exhibit 99.1, shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in any such filing, except as expressly set forth by specific reference in such a filing. This Current Report will not be deemed an admission as to the materiality of any information in this Current Report that is required to be disclosed solely by Regulation FD.

 

Forward-looking statements in this Current Report, including Exhibit 99. 1 attached hereto, or hereafter, including in other publicly available documents filed with the Securities and Exchange Commission (“Commission”), reports to the stockholders of the Company and other publicly available statements issued or released by us involve known and unknown risks, uncertainties and other factors which could cause our actual results, performance (financial or operating), or achievements to differ from the future results, performance (financial or operating), or achievements expressed or implied by such forward-looking statements. Such future results are based upon the Company’s best estimates based upon current conditions and the most recent results of operations. These risks include, but are not limited to, the risks associated with the Reverse Stock Split and the risks set forth in such other documents filed with the Commission, each of which could adversely affect our business and the accuracy of the forward-looking statements contained herein. Our actual results, performance or achievements may differ materially from those expressed or implied by such forward-looking statements.

 

Item 9.01. Financial Statements and Exhibits

 

(d) Exhibits

 

Exhibit No.   Description
3.1   Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Evofem Biosciences, Inc., filed November 5, 2026
3.2   Certificate of Correction, filed November 17, 2026
99.1   Press Release dated November 18, 2026
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  EVOFEM BIOSCIENCES, INC.
   
Dated: November 18, 2026 By: /s/ Saundra Pelletier
    Saundra Pelletier
    Chief Executive Officer

 

 

 

 

Exhibit 99.1

 

A blue and white logo

AI-generated content may be incorrect.

 

Evofem Biosciences Effects Previously-Approved

 Reverse Stock Split

 

— CUSIP number for Evofem will change to 30048L401 on November 18, 2026 —

 

— Ticker symbol will change to “EVFMD” for 20 business days, then revert to “EVFM” —

 

SAN DIEGO, CA, November 18, 2026 — Women’s health innovator Evofem Biosciences, Inc. (OTCID: EVFM) today announced a 1-for-1,500 reverse stock split of the Company’s common stock, which was approved by the stockholders of the Company at the Annual Meeting of Stockholders held on November 26, 2025.

 

●On Wednesday November 18, 2026, the Company’s common stock will open for trading under a new CUSIP (30048L401) on the OTC Basic Market, on a split-adjusted basis, under the ticker symbol “EVFMD.”

 

●After 20 business days, the ticker symbol will change back to “EVFM.”

 

The reverse stock split is intended to ensure the Company has enough authorized shares of common stock to cover the number of common shares underlying the Company’s financial instruments on a fully diluted basis.

 

The 1-for-1,500 reverse stock split will automatically convert 1,500 current shares of the Company’s common stock into one share of common stock. No fractional shares will be issued in connection with the reverse stock split. Stockholders who would otherwise hold a fractional share of the Company’s common stock will receive a cash payment in lieu thereof at a price equal to that fraction to which the stockholder would otherwise be entitled multiplied by the closing trading price of the common stock on the OTC Basic Market on Tuesday, November 17, 2026, and rounded down to the nearest whole cent.

 

The reverse split will reduce the number of shares of outstanding common stock from approximately 132,530,081 shares, the number of shares outstanding as of November 17, 2026, which was the Record Date for this transaction, to approximately 88,353 shares. Proportional adjustments will be made to the exercise and conversion prices of the Company’s outstanding stock options, warrants, purchase rights, and convertible notes, and to the number of shares issued and issuable under the Company’s stock incentive plans.

 

Stockholders holding their shares electronically in book-entry form are not required to take any action to receive post-split shares. Stockholders owning shares through a bank, broker or other nominee will have their positions automatically adjusted to reflect the reverse stock split, subject to brokers’ particular processes, and will not be required to take any action in connection with the reverse stock split. For those stockholders holding physical stock certificates, the Company’s transfer agent, Pacific Stock Transfer, will send instructions for exchanging those certificates for shares held electronically in book-entry form or for new certificates, in either case representing the post-split number of shares, and any payments in cash in lieu of fractional shares, if applicable.

 

About Evofem Biosciences, Inc.

 

Evofem Biosciences is a San Diego-based pharmaceutical company commercializing two FDA-approved sexual and reproductive health products:

 

●PHEXX® (lactic acid, citric acid, and potassium bitartrate) – the first and only hormone-free, on-demand prescription contraceptive vaginal gel. Visit phexx.com to learn more and for important safety information.

 

●SOLOSEC® (secnidazole) 2g oral granules – an FDA-approved oral antibiotic for the treatment of two sexual health diseases: bacterial vaginosis (BV), a common vaginal infection, in females 12 years of age and older, and trichomoniasis, a common sexually transmitted infection (STI), in people 12 years of age and older. SOLOSEC provides a complete course of therapy in just one dose. Visit solosec.com to learn more and for important safety information.

 

PHEXX® and SOLOSEC® are registered trademarks of Evofem Biosciences, Inc.

 

Contact

 

Amy Raskopf

Evofem Biosciences, Inc.

araskopf@evofem.com

(917) 673-5775

 

###

 

 

 

Filing Exhibits & Attachments

10 documents

Keep reading